Name of the Substance

Similar documents
Resolution 59/8 Promotion of measures to target new psychoactive substances and amphetamine-type stimulants

Drugs and Poisons Legislation Amendment (New Psychoactive and Other Substances) Act 2013 No 70

Criminal Justice (Psychoactive Substances) Bill Regulatory Impact Analysis

EWS manual information flow alert database on NPS

Expert Committee on Drug Dependence Thirty sixth Meeting Geneva, June 2014

Proposal for a COUNCIL DECISION

Expert Peer Review for Carfentanil

Proposal for a COUNCIL IMPLEMENTING DECISION

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

9668/15 JV/PN/np 1 DGD2C

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Ketamine. Expert peer review on critical review report (1) 35 th Expert Committee on Drug Dependence, Hammamet, Tunisia June 4-8, 2012

POISONS SCHEDULING. Monique Reyes Senior Pharmaceutical Officer Pharmaceutical Regulatory Unit NSW Ministry of Health

The new laws. Why are the laws changing? From 1st April 2011, it will also be illegal:

Act on Narcotic Drugs and Psychotropic Substances and Precursors thereof

Measuring Illicit Tobacco Markets

Legalization of Cannabis: The Way Forward

Regulating Marijuana in California

Improving the regulatory framework for electronic cigarettes (e-cigarettes) and emerging tobacco and nicotine-delivery products

Legalization of Cannabis- Overview

COMBATING THE ILLICIT TRADE OF CIGARETTE AND TOBACCO PRODUCTS ANTI ILLICIT TRADE CONFERENCE CAPE TOWN, SOUTH AFRICA 9 11 NOVEMBER 2015

Cannabis Legalization August 22, Ministry of Attorney General Ministry of Finance

Yukon s Proposed Framework for. Legalized Cannabis 30 GRAMS MINIMUM AGE

Organization of American States OAS Inter-American Drug Abuse Control Commission CICAD. Multilateral Evaluation Mechanism MEM.

WHO Expert Committee on Drug Dependence Pre-Review: Extracts and tinctures of cannabis. Expert Peer Review 2

REPORTING INSTRUMENT

AMA Submission House of Representatives Standing Committee on Health and Ageing inquiry into the

Legalization of Recreational Cannabis

ALCOHOL & DRUG USE INCIDENT MANAGEMENT POLICY

THE EXPERT ADVISORY COMMITTEE ON DRUGS (EACD) ADVICE TO THE MINISTER ON:

Informal meeting of the Justice and Home Affairs Ministers Sopot July 2011

Federation of Saint Kitts and Nevis

Schedules of Controlled Substances: Temporary Placement of Furanyl Fentanyl. AGENCY: Drug Enforcement Administration, Department of Justice

REPORTING INSTRUMENT

REPORTING INSTRUMENT

Schedules of Controlled Substances: Temporary Placement of the Synthetic. AGENCY: Drug Enforcement Administration, Department of Justice.

RESPONSE FROM ALTRIA:

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis

are being added to products that have the same or similar effects exercised emergency scheduling authority to control five (5)

Problem Which option Additional option Additional comments definition Yes No change No further observations.

SUNRISE, FLORIDA ORDINANCE NO.

REPORTING INSTRUMENT

COMMISSION OF THE EUROPEAN COMMUNITIES COMMISSION STAFF WORKING DOCUMENT

Marijuana 101. Cristal Connelly- Marijuana Prevention & Education Consultant Washington State Department of Health- Community Based Prevention

Running Head: LEGALIZATION OF MARIJUANA 1 LEGALIZATION OF RECREATIONAL MARIJUANA IN CALIFORNIA

What about off-duty marijuana consumption? Taxes & revenue Will cities get any revenue from the sale of marijuana?

Substance Misuse Policy

Mark W. Caverly, Chief Liaison and Policy Section

An Overview of the Government of Canada s Approach to Legalize, Regulate and Restrict Access to Cannabis. February 2018

Methodological approach to measure drug trafficking-related IFFs

Legalization, Regulation and Restriction of Access to Cannabis

Counterfeit Medicinal Products. FINLAND Roschier, Attorneys Ltd.

OXYCONTIN Diversion & Abuse Drug Enforcement Administration Office of Diversion Control October 2003

Free copies of the Rick Simpson Protocol are available to community members for download on social media, and home delivery is offered.

Requirements of the International Drug Control Conventions, Catherine Muganga Legal Officer, UNODC Feb 2015

Greens NSW Drug Regulation and Harm Minimisation Policy

This questionnaire will ask you about approved medical use of extracts and tinctures of cannabis at national level.

Organization of American States OAS Inter-American Drug Abuse Control Commission CICAD. Multilateral Evaluation Mechanism MEM.

Butyrfentanyl (Butyrylfentanyl) Critical Review Report Agenda item 4.2

Questionnaire 1 of 5: Cannabis Plant and Cannabis Resin. Introduction

ARKANSAS STATE UNIVERSITY GOVERNING PRINCIPLES FOR THE USE OF CONTROLLED SUBSTANCES IN RESEARCH

Cannabis Legalization and Regulation in British Columbia Discussion Paper

Guidance for Industry DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

The Canadian context for cannabis policy and public health approaches to substance use

Drug Trend Bulletin Issue 13 September 2016.

Unofficial translation /Ministry of Social Affairs and Health. No. 548/2008. Government Decree on Narcotics Control

Misuse of Drugs (Medicinal Cannabis) Amendment Bill

Counterfeit Pharmaceuticals. in Canada. The counterfeit criminal market. in Canada. No country is immune from counterfeit drugs

FACT SHEET. A selection of internet-based information. Methedrone (bk-pmma)

RECREATIONAL CANNABIS LEGALIZATION IN ONTARIO

Changing practice to support service delivery

Statistical Bulletin. The methamphetamine market: police detainee perspectives. Trends in reported methamphetamine use. April 2018

Written Brief to the Standing Committee on Health

It is illegal to serve more than 40 oz of beer, 1 liter of wine or 4 oz distilled spirits at one time to a guest.

National Rift Valley Fever Contingency Plan

International Narcotics Control Board. United Nations Convention against Illicit Traffic In Narcotic Drugs and Psychotropic Substances of 1988

Review of Controlled Drugs and Substances Act

WHO Framework Convention on Tobacco Control

Proposal for a COUNCIL DECISION

Public consultation for the 2016 evaluation of the EU Drugs Strategy and Action Plan on Drugs

ALCOHOL CONTROL POLICY IN LITHUANIA

QUESTIONNAIRE. Submission Information. Information for follow-up purposes. Head of International Drug Policy, Home Office

Schedules of Controlled Substances: Temporary Placement of U into. AGENCY: Drug Enforcement Administration, Department of Justice.

Schedules of Controlled Substances: Placement of Furanyl fentanyl, 4- Fluoroisobutyryl fentanyl, Acryl fentanyl, Tetrahydrofuranyl fentanyl, and

Public consultation for the 2016 evaluation of the EU Drugs Strategy and Action Plan on Drugs

M I L L E R T H O M S O N LLP Barristers & Solicitors, Patent & Trade Mark Agents

Use of Light, Mild, Low, or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products

What is Drug Trends? funded by the Australian Government under the Substance Misuse Prevention and Service Improvement Grants Fund

Launch of the INCB Annual Reports 2015

Appearance before House of Commons Standing Committee on Health as part of its Study on the Government s Role in Addressing Prescription Drug Abuse

Colorado s Cannabis Experience Doug Friednash

Cannabis Legalization

Regulatory Considerations for Legalized Marijuana. Nick Brechun, Colorado Julie Quinn, Minnesota

CSBA Sample Board Policy

Schedules of Controlled Substances: Temporary Placement of FUB-AMB into Schedule I. AGENCY: Drug Enforcement Administration, Department of Justice.

NIJ s Drugs and Crime Research Portfolio

SUBJECT: Cannabis legislation and implications for the City of Burlington

City of Houston, Texas, Ordinance No

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

Substance Misuse (Drugs, Alcohol and Tobacco) Policy

Transcription:

Name of the Substance 0. Do you have any information on the use of this substance in your country either for medical, scientific, industrial or other professional purposes, for non-medical consumption or recreational purposes, or for any other purpose? Yes If Yes, please specify:.. No If you responded No, please submit this form and proceed to the next substance. Section 1. LEGITIMATE MEDICAL OR SCIENTIFIC USE Questions in Section 1 are intended for the Ministry of Health and National Regulatory Authority Please read the entire section before responding to questions 1.1 Do you know if approved medical products containing this substance are available in your country for human or veterinarian indications? (Check all that apply) Human medical product Veterinary medical product Not available in medicinal products 1.2 What are the therapeutic indications approved for this substance in your country?... 1.3 Please indicate the marketed name, dosage form(s) and strength(s) of this substance available in your country; also indicate (under Remarks) any special properties such as slow release, etc. Marketed Name Dosage form Remarks examples: tablet, oral solution 1

1.4 Is this substance currently used in medical or scientific research (excluding use as an analytical reference standard) in your country (e.g. is it in clinical trials for any human or veterinary indication)? Yes No If Yes, please specify Section 2. LEGITIMATE NON-MEDICAL/NON-SCIENTIFIC USE 2.1 Is this substance used for industrial or other non-medical/non-scientific purposes in your country? Yes No If Yes to question 2.1 please specify:.. 2.2 What is the origin/source of this substance when used for legitimate non-medical/nonscientific use? Manufactured in your own country Imported Both manufactured in your own country and imported 2.3 What is the estimated amount of this substance used annually in your country for any legitimate non-medical/non-scientific use? kg litre per year 2.4 Any additional information related to the questions in Section 2........... Section 3. CULTURAL, RELIGIOUS OR CEREMONIAL USE 3.1 Is this substance used for cultural, religious or ceremonial purposes in your country? 2

Yes No If Yes, please specify by whom, for what purposes, route of administration and typical amounts used:........ 3.2 Any additional comments related to the questions in Section 3........... Section 4. EPIDEMIOLOGY OF NON-MEDICAL/NON-SCIENTIFIC USE USE FOR PSYCHOACTIVE PURPOSES OR RECREATIONAL DRUG USE Questions in Section 4 are intended for national research organizations or competent agencies/authorities on substance abuse Please read the entire section before responding to questions 4.1 Is this substance misused for its psychoactive properties (as a recreational drug) in your country? Yes No If you responded Yes to 4.1, please answer the following questions (numbers 4.2 to 4.12); if you responded No or Do not know to 4.1, you do not need to answer questions number 4.2 to 4.12. 4.2 By what route(s) of administration is this substance used for non-medical/non-scientific purposes in your country (please check all that apply): Oral Injection Inhalation Sniffing Smoking Do not know Other (please specify).. What is the main route of administration for this substance?......... 4.3 In which formulations is this substance used for non-medical/non-scientific purposes in your country: (please check all that apply) Powder 3

Tablets Liquid or solution for oral administration/use Solution for injection Other (please specify):.. 4.4 What is (are) the source(s) of this substance for non-medical/non-scientific use in your country? (Please check all that apply) Legal manufacturing Legal trade Illegal manufacturing Diversion (from legal supply chain) Smuggling (from other countries) Other (please specify): 4.5 Are there any specific subpopulations in your country known to misuse this substance? Yes No If Yes to question 4.5 please specify which groups:. 4.6 Please provide any information on the extent and magnitude of public-health problems or social harm from the use of this substance in your country: 4.7 As an expert, to what level is it your perception that this substance has a negative healthimpact originating from this substance's non-medical consumption? Negligible Substantial Serious If Substantial or Serious, please specify: 4.8 Are you aware of any emergency room/department visits related to the use of this substance? If Yes, please specify: 4.9 Please list the adverse effects (non-fatal intoxications etc.) presented for this substance at the emergency room/department: 4

.............. 4.10 If available, please provide the number of deaths where this substance was involved (provide data for the most recent completed year available): Number of deaths Year a. This substance was the only substance involved b. Other substances were also involved c. Unknown if other substances were involved Total (a+b+c) 4.11 Are you aware of people presented to drug dependence treatment due to the use of this substance? Yes No If Yes, please specify: 4.12 Please provide any additional comments to the questions in Section 4........... Section 5. CURRENT CONTROL Questions in Section 5 are intended for the national competent authority for drug control 5.1. Is this substance currently controlled under national legislation in order to regulate its availability in your country? Yes No If Yes to 5.1, please continue with question 5.2; otherwise skip questions 5.2 5.6 and continue with question 5.7. If Yes, please indicate on which legislation the current control is based and provide the exact title of the Act: (please check all that apply) Medicines act: Controlled substances act, etc.: Tobacco or alcohol control act:. Other consumer protection act:.. Criminal law act:.. 5

Other specific legislation (analog; generic; temporary/emergency; etc.):. Other:.. 5.2 What is the scope of this control: (please check all that apply) Production Manufacture Export Import Distribution Use Possession Other (please specify):.. 5.3 Is the current control a temporary provision? Yes If Yes, for how long/since when No 5.4 Have there been challenges to implementing controls of this substance in your country? Yes No If Yes to question 5.4 please specify in which area and explain: (please check all that apply) Forensic laboratory capacity:. Resources to implement and/or enforce:.... Expertise to detect or enforce:... Other:. 5.5 Are there illicit activities involving this substance: (please check all that apply) Manufacture of the substance by chemical synthesis Manufacture of the substance by extraction from other products Production of consumer products (dosage forms, packaging) Trafficking Diversion Internet sales: Internet sales (seller or website located in your country) Internet sales (from abroad to buyers in your country) 6

Internet sales (other or location of sellers and website unknown) Sales to people who use this substance Other (please specify): 5.6 Number of seizures: 2014: 2015:... 2016:... 5.7 If this substance would be placed under international control, will your country have the capacity to enforce the control at the national level? Yes No 5.8 If this substance would be placed under international control, does your country have the forensic laboratory capacity to analyse the substance (identification, purity)? Yes No 5.9 Any additional information related to the questions in Section 5. 7